The new framework collaboration will support due diligence into ALSA’s potential investments, which will assist with their investment de-risking
Novel approach driven by GN Corp Japan with potentials in neurological illnesses
Company will expand the existing production site in Wuxi to significantly increase biopharma single-use assemblies and custom design capabilities
The planned Phase 1 study is a double-blind, randomized, placebo-controlled dose-escalation study in healthy adult subjects and AD patients
In addition, common light chain antibodies generated by RenLite mice can greatly improve the efficiency of downstream assembly of complex drug molecules such as bispecific antibodies and bispecific antibody-drug conjugates (bsADCs)
The respective expertise of Lonza and Integral Molecular will benefit drug developers in the assessment of the risk for off-target binding and activation
Aflibercept is the second biosimilar product that has entered the clinical trial phase after biosimilar Adalimumab
Immune response confirmed in stand-alone influenza vaccine and combination vaccine with a potential path forward for both
The peptide-based vaccine induces a t cell-dependent response
Collaboration to target bacterial and viral pathogens including HIV, SARS-CoV-2, antimicrobial-resistant pathogens, and tuberculosis
Subscribe To Our Newsletter & Stay Updated
